Last updated on November 2018

Post-Marketing Surveillance Study of OTEZLA

Brief description of study

To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica

  1. Planned registration period 2 years
  2. Planned surveillance period for 4 years from 6 months after launch

Clinical Study Identifier: NCT03284879

Find a site near you

Start Over

Tugi dermatology clinic

Kitakyushu, Japan
  Connect »